Tc Land Expression is a personalized medicine company dedicated to the development of companion diagnostics in Immune Mediated Disorders and biomarkers in Solid Organ Transplantation.

Through its strong expertise in immunology and a preferred access to patient cohorts, Tc Land Expression develops and validates non-invasive multi-genes molecular diagnostic blood tests.

Upon acquisition by Firalis and thanks to the cumulated know-how of the latter, Tc Land submitted a cutting-edge research project to Horizon 2020, RABIOPRED ; and has been selected by the European Community to receive 5 Million EUR of subvention that covers all costs of the project.

For more information on Tc Land Expression S.A., please visit